Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Mar;19(3):169-184.
doi: 10.1038/s41573-019-0038-z. Epub 2019 Sep 6.

Translating gammadelta (γδ) T cells and their receptors into cancer cell therapies

Affiliations
Review

Translating gammadelta (γδ) T cells and their receptors into cancer cell therapies

Zsolt Sebestyen et al. Nat Rev Drug Discov. 2020 Mar.

Abstract

Clinical responses to checkpoint inhibitors used for cancer immunotherapy seemingly require the presence of αβT cells that recognize tumour neoantigens, and are therefore primarily restricted to tumours with high mutational load. Approaches that could address this limitation by engineering αβT cells, such as chimeric antigen receptor T (CAR T) cells, are being investigated intensively, but these approaches have other issues, such as a scarcity of appropriate targets for CAR T cells in solid tumours. Consequently, there is renewed interest among translational researchers and commercial partners in the therapeutic use of γδT cells and their receptors. Overall, γδT cells display potent cytotoxicity, which usually does not depend on tumour-associated (neo)antigens, towards a large array of haematological and solid tumours, while preserving normal tissues. However, the precise mechanisms of tumour-specific γδT cells, as well as the mechanisms for self-recognition, remain poorly understood. In this Review, we discuss the challenges and opportunities for the clinical implementation of cancer immunotherapies based on γδT cells and their receptors.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Chien, Y. H., Meyer, C. & Bonneville, M. Gammadelta T cells: first line of defense and beyond. Annu. Rev. Immunol. 32, 121–155 (2014). - DOI - PubMed - PMC
    1. Girardi, M. et al. Regulation of cutaneous malignancy by γδ T cells. Science 294, 605–609 (2001). - DOI - PubMed - PMC
    1. Silva-Santos, B., Serre, K. & Norell, H. Gammadelta T cells in cancer. Nat. Rev. Immunol. 15, 683–691 (2015). - DOI - PubMed - PMC
    1. Ma, Y. et al. Contribution of IL-17-producing γ δ T cells to the efficacy of anticancer chemotherapy. J. Exp. Med. 208, 491–503 (2011). - DOI - PubMed - PMC
    1. Dadi, S. et al. Cancer immunosurveillance by tissue-resident innate lymphoid cells and innate-like T cells. Cell 164, 365–377 (2016). - DOI - PubMed - PMC

Publication types

MeSH terms

Substances